D. Mannino

Use of insulin detemir in pregnancy: a report on 10 Type 1 diabetic women

bromatosis 1 ⁄ Noonan syndrome associated with Hashimoto’s thyroiditis and vitiligo. Acta Derm Venereol 2006; 86: 80–81. 6 Zaka-ur-Rab Z, Chopra K. Diabetes mellitus in neurofibromatosis I: an unusual presentation. Indian Pediatr 2005; 42: 185–186. 7 Tekin F, Ozutemiz O, Carcurgan S, Ilter T. Autoimmune haemolysis as an unusual cause of anaemia in von Recklinghausen’s disease. Neth J Med 2004; 62: 337–339. 8 Corominas H, Guardiola JM, Matas L, Vázquez G. Neurofibromatosis and systemic lupus erythematosus. A matter of coincidence? Clin Rheumatol 2003; 22: 496–497. 9 Migita K, Kawabe Y, Mori M, Hirose R, Kimura H, Hamada H et al. Mixed connective tissue disease associated with Von Recklinghausen’s neurofibromatosis. Intern Med 2001; 40: 363– 364. 10 Tarrass F. Focal and segmental glomerulosclerosis and Von Recklinghausen’s neurofibromatosis: coincidental or associated? Saudi J Kidney Dis Transpl 2008; 19: 453–454. 11 Yesudian PD, Wilson NJ, Parslew R. Bullous pemphigoid and neurofibromatosis—a chance association requiring special vigilance. Clin Exp Dermatol 2000; 25: 658–659. 12 Feuillet L, Boudinet H, Casseron W, Uzenot D, Pelletier J, Cherif A. Multiple sclerosis associated with neurofibromatosis type I. Rev Neurol 2004; 160: 447–451.

Insulin analogs and pregnancy: an update

It is well known that good metabolic control maintained throughout pregnancy reduces maternal and fetal complications in diabetes. Before conception and throughout pregnancy, insulin therapy needs to be optimized and, in this context, the insulin analogs currently available in the market may help to achieve good metabolic control. We therefore review here what is known about the potential benefits and risks related to the use of these new insulins in pregnancy. Clinical and experimental data on insulin aspart and lispro strongly suggest that they have no adverse maternal or fetal effects during pregnancy in women with pregestational and gestational diabetes, and that their use results in improved glycemic control, fewer hypoglycemic episodes, and improved patient satisfaction. At present there are no published data on the use of glulisine in pregnancy. Insulin glargine during pregnancy is not recommended but, in the last years, larger surveys (retrospective and case–control studies) have been published on this field and, to date, results of about 335 pregnancies with type 1 diabetes are available showing an incidence of congenital malformation similar to that obtained with human insulin. There are no published data concerning the use of detemir in pregnancy but the results of a prospective study are expected in 2010.

Perinatal outcomes associated with the use of glargine during pregnancy

Aims  Insulin glargine (IG), with its non‐peaking action profile, might be useful in diabetic pregnancy. However, data on its safety are limited and its use during pregnancy is not recommended. This study focused on the effects of IG on perinatal outcome, particularly to estimate the rate of congenital anomalies and birthweight.

Care of diabetes in pregnancy in Italy: structural and organizational aspects.

© 2008 The Authors. Journal compilation